Hengrui Pharma(SH:600276) 智通财经网·2025-09-05 01:20Core Viewpoint - Heng Rui Medicine has entered into an agreement with Braveheart Bio to license its innovative drug HRS-1893 for a total of $75 million, with potential milestone payments reaching up to $1.013 billion based on clinical development and sales performance [1][2]. Group 1: Agreement Details - Heng Rui Medicine will grant Braveheart Bio exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1]. - Braveheart Bio will pay an upfront fee of $65 million, consisting of $32.5 million in cash and $32.5 million in equity, along with a $10 million milestone payment upon completion of technology transfer, totaling $75 million [1]. - Heng Rui Medicine is eligible for additional milestone payments related to clinical development and sales, which could reach up to $1.013 billion [1]. Group 2: Drug Information - HRS-1893 is a myosin selective inhibitor that works by inhibiting the ATPase activity of cardiac myosin, thereby reducing excessive contraction of the myocardium, decreasing left ventricular hypertrophy, and improving diastolic relaxation [2]. - The drug is currently in Phase III clinical development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) [2].